The discussion highlighted a pivotal phase III trial launch for a TCR T-cell therapy targeting relapse prevention in heme malignancies, with strong early and long-term data, manufacturing improvements, and a robust trial design. Regular data updates and expansion into new indications are planned.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.